Maksim LabkouskiAcelyrin (NASDAQ:SLRN) traded sharply lower on Tuesday after the company and its California-based rival Alumis (NASDAQ:ALMS) reaffirmed their commitment…
Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash…
